Introduction {#s1}
============

The [Reproducibility Project: Cancer Biology](https://osf.io/e81xl/wiki/home/) (RP:CB) is a collaboration between the [Center for Open Science](https://cos.io) and [Science Exchange](https://www.scienceexchange.com) that seeks to address concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology ([@bib9]). For each of these papers, a Registered Report detailing the proposed experimental designs and protocols for the replications was peer reviewed and published prior to data collection. The present paper is a Replication Study that reports the results of the replication experiments detailed in the Registered Report ([@bib11]) for a paper by [@bib56] and uses a number of approaches to compare the outcomes of the original experiments and the replications.

[@bib56] reported that colon cancer cell subpopulations with high Wnt activity correlated with markers of cancer stems cells (CSC) and displayed enhanced tumor initiating potential. Moreover, factors secreted from cancer-associated fibroblasts (CAFs), which are an important component of the stroma, such as HGF, were reported to play a role in the formation of the CSC niche and tumorigenicity by activating the Wnt signaling pathway ([@bib56]). This was demonstrated using *in vitro* clonogenicity and *in vivo* tumorigenicity assays, suggesting Wnt activity defines CSCs and is regulated by the microenvironment.

The Registered Report for the paper by [@bib56] described the experiments to be replicated (Figures 2F, 6D and 7E), and summarized the current evidence for these findings ([@bib11]). Since that publication additional studies have reported a relationship between Wnt activity, using a Wnt reporter like [@bib56], and CSC properties in various malignancies, including colorectal, lung, gastric, and breast cancer ([@bib24]; [@bib53]). Moreover, recent studies have also reported CSC properties from cells with high expression of Wnt target genes, such as *LGR5* ([@bib7]; [@bib25]; [@bib48]). Furthermore, recent studies have continued to examine the role of the microenvironment and cancer stemness. Niche factor requirements in colorectal tumors were found to decrease during tumorigenesis ([@bib13]; [@bib26]). While a new modeling approach suggested stem cell functionality during colorectal tumor expansion was defined by secreted factors from CAFs rather than cell-intrinsic properties ([@bib12]; [@bib32]).

[@bib56] also reported CD133, the combination of CD29/CD24, and the combination of CD44/CD166 were correlated with high Wnt activity. CD133 has been suggested to mark CSCs in various tumor types, although the accuracy as a CSC biomarker has been highly controversial ([@bib15]). In colorectal cancer, variation in clonogenic potential with specific cell populations have been reported ([@bib30]), with CD133^+^ cells reported to be associated with the CSC population in two separate studies ([@bib40]; [@bib45]), while [@bib49] reported both CD133^+^ and CD133^-^ populations were capable of forming colonospheres *in vitro* and were serially tumorigenic in mice. Variation has also been reported in independent studies that examined CD133 expression to define a clonogenic subfraction when examining the same cell line, HCT116 ([@bib5]; [@bib8]). As such, other studies have reported other markers, such as CD44 and CD166, to be more robust in identifying colorectal CSCs ([@bib6]; [@bib41]). There is also variation of the significance of CD24 expression in colorectal cancer, while the significance of CD29 needs further investigation, although the presence of these molecules have been associated with CSC characteristics ([@bib17]; [@bib21]; [@bib37]).

The outcome measures reported in this Replication Study will be aggregated with those from the other Replication Studies to create a dataset that will be examined to provide evidence about reproducibility of cancer biology research, and to identify factors that influence reproducibility more generally.

Results and discussion {#s2}
======================

Generation and characterization of primary spheroidal cultures of colon cancer cells {#s2-1}
------------------------------------------------------------------------------------

To assess Wnt signaling activity in colon cancer stem cells (CSC), we transduced primary spheroidal cultures of colon cancer cells with the same Wnt reporter construct as the original study, which used a TCF/LEF-1 responsive promoter to drive expression of green fluorescent protein (GFP) (TOP-GFP; [@bib44]). The experimental approach to generate TOP-GFP expressing CSC cultures was described in Protocol 1 of the Registered Report ([@bib11]). We used three independent spheroidal cultures, one used in the original study (Co100) and two derived from primary human colorectal cancer tissues (CSC1 and E450). The three cultures were transduced with TOP-GFP and single-cell TOP-GFP cultures were isolated. This approach, similar to the original study, was done to exclude variation in lentiviral integration and copy number between cells ([@bib55]). The single-cell-derived TOP-GFP cultures displayed heterogeneity in Wnt signaling, similar to what was reported in the original study ([Figure 1A,B](#fig1){ref-type="fig"}).

![Analysis of CSC marker expression in TOP-GFP cultures.\
(**A**) Representative images of the three independent single-cell-cloned CSC cultures, lentivirally transduced with TOP-GFP. Phase contrast (top) and fluorescence microscopy (bottom) for each of the cultures indicated. Bar = 90 µm. (**B**) Single parameter histograms for GFP intensity for each of the TOP-GFP single-cell-cloned CSC cultures with the TOP-GFP^low^ (10% lowest) and TOP-GFP^high^ (10% highest) populations indicated. (**C**) Single parameter histograms for the indicated cell surface markers for each of the indicated cultures. Gray denotes TOP-GFP^low^ (10% lowest) and green denotes TOP-GFP^high^ (10% highest) populations. (**D**) Density plots for CD29/CD24 and CD44/CD166 from TOP-GFP^low^ (gray) and TOP-GFP^high^ (green) populations of each culture. Additional details for this experiment can be found at <https://osf.io/tfy28/>.](elife-45426-fig1){#fig1}

The three TOP-GFP cultures were then sorted into the highest and lowest 10% of TOP-GFP-expressing cells by fluorescence-activated cell sorting and analyzed for expression of the same cell surface markers reported in the original study. This experiment is similar to what was reported in [Figure 2F](#fig2){ref-type="fig"} of [@bib56] and described in Protocol 2 in the Registered Report ([@bib11]). We found the TOP-GFP^high^ populations were more enriched for CD133^+^ or CD166^+^ cells compared to the TOP-GFP^low^ populations for each of the three cultures ([Figure 1C,D](#fig1){ref-type="fig"}). There were also more CD29^+^ cells in the TOP-GFP^high^ populations for each of the three cultures, while the two TOP-GFP populations were mostly similar for CD24 expression. We also found the TOP-GFP^low^ populations from E450 and CSC1 cultures were more enriched for CD44^+^ cells, while both the populations displayed similar expression for Co100. The original study stated that CD133, the combination of CD29/CD24, and the combination of CD44/CD166 were correlated with the TOP-GFP^high^ population ([@bib56]). However, since the degree that each of the markers correlated with the TOP-GFP^high^ and TOP-GFP^low^ populations were not completely reported in the original study, it is difficult to directly compare to the results reported in this replication attempt. To summarize, for this experiment we found results that varied in direction relative to the original study.

Clonogenicity of TOP-GFP CSC cultures {#s2-2}
-------------------------------------

The three TOP-GFP cultures were then used to assess the clonogenic potential of the cells using a limiting-dilution assay. Different TOP-GFP expressing fractions were examined to test if variation in TOP-GFP levels resulted in differential clonogenicity. Additionally, TOP-GFP^low^ fractions were treated with conditioned medium derived from myofibroblasts (MFCM) or hepatocyte growth factor (HGF), with and without a specific c-Met inhibitor (PHA665752), to test if myofibroblast-secreted factors increased the clonogenic potential. This experiment is similar to what was reported in Figure 6D of [@bib56] and described in Protocol 3 in the Registered Report ([@bib11]). We first performed a pilot assay of the dilution curve in untreated conditions and observed the clonogenic potential in the TOP-GFP^high^ fractions were greater than the TOP-GFP^low^ fractions for each of the cultures tested ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). We then proceeded with the experiment to test all of the conditions specified in the Registered Report and reported in the original study. Similar to the pilot assay, we found the clonogenic potential of TOP-GFP^high^ cells were greater than TOP-GFP^low^ cells for each of the three cultures ([Figure 2](#fig2){ref-type="fig"}). We also observed that the clonogenicity of TOP-GFP^low^ cells were increased in the presence of MCFM or HGF, which was reduced when PHA665752 was included, although to varying degrees across the different cultures. Interestingly, PHA665752 treatment on the whole population of TOP-GFP cells (TOP-GFP^whole^) had varying effects on the clonogenicity among the different cultures tested. Both the Co100 and E450 cultures had decreased clonogenicity in the presence of PHA665752, while CSC1 cultures were increased. The original study reported the clonogenic potential of the TOP-GFP^high^ fraction was greater compared to TOP-GFP^low^ cells, with the clonogenic potential of TOP-GFP^low^ cells enhanced with MFCM, or HGF, treatment, almost to the level of TOP-GFP^high^ cells, which was blocked with PHA665752 ([@bib56]). PHA665752 was also reported to have no effect on the clonogenicity of TOP-GFP^whole^ cells ([@bib56]). The HGF and PHA665752 concentrations were the same between the original study and this replication attempt (25 ng/ml and 500 nM, respectively) as was the MFCM treatment that used a 1:2 dilution of MFCM diluted in CSC medium. As suggested during peer review of the Registered Report ([@bib14]), we also determined the concentration of HGF in MFCM, which was determined by enzyme-linked immunosorbent assay (ELISA) to be 0.61 ng/ml. The original study reported HGF production in MFCM was \~120 ng/ml (Figure 5E; [@bib56]) or approximately 200 times higher than what we observed. Other studies that measured the amount of HGF in MFCM using the same cell line (18Co) and timeline (24 hr) reported concentrations of \~0.4 ng/ml ([@bib47]) and \~6 ng/ml ([@bib59]). The variation of HGF production might be explained by differences in assay reagents, such as the generation of the standard curve ([@bib23]) and variability in microplate surface properties ([@bib33]). Further, HGF production has been shown to be influenced by other soluble factors, such as transforming growth factor-β (TGF-β) and basic fibroblast growth factor (FGF2) ([@bib38]). The variation in HGF production in MFCM between the original study and this replication attempt might account for any observed differences in outcomes and should be taken into account when interpreting these results. Importantly, though, observing and reporting all outcomes are informative to establish the range of conditions under which a given phenotype can be observed ([@bib1]).

![Clonogenicity assay of TOP-GFP cultures.\
A limiting-dilution assay was performed on the TOP-GFP^low^, TOP-GFP^high^, or TOP-GFP^whole^ populations of the three indicated TOP-GFP cultures. Cells were left untreated, or treated with 25 ng/ml HGF, 1:2 dilution of MFCM, or 500 nM PHA-665752 (PHA), as indicated. The bar graphs present the clonogenic potential of each culture with error bars representing 95% confidence intervals (y-axis is log~2~ scale). This experiment was performed once for each culture. See Materials and methods and Registered Report ([@bib11]) for details on limiting-dilution statistics and scheme. Planned contrast between TOP-GFP^low^ vs TOP-GFP^high^: E450 (*χ*^2^ = 39.8, uncorrected *p*=2.82×10^−10^, corrected *p*=1.69×10^−9^); CSC1 (*χ*^2^ = 4.82, uncorrected *p*=0.028, corrected *p*=0.169); Co100 (*χ*^2^ = 7.59, uncorrected *p*=0.0059, corrected *p*=0.035). Planned contrast between TOP-GFP^low^ vs TOP-GFP^low^ + HGF: E450 (*χ*^2^ = 1.49, uncorrected *p*=0.223, corrected *p*\>0.99); CSC1 (*χ*^2^ = 0.337, uncorrected *p*=0.562, corrected *p*=0.99); Co100 (*χ*^2^ = 12.7, uncorrected *p*=3.70×10^−4^, corrected *p*=0.0022). Planned contrast between TOP-GFP^low^ vs TOP-GFP^low^ + MFCM: E450 (*χ*^2^ = 1.96, uncorrected *p*=0.162, corrected *p*=0.969); CSC1 (*χ*^2^ = 4.18, uncorrected *p*=0.041, corrected *p*=0.245); Co100 (*χ*^2^ = 28.7, uncorrected *p*=8.26×10^−8^, corrected *p*=4.96×10^−7^). Planned contrast between TOP-GFP^low^ + HGF vs TOP-GFP^low^ + HGF + PHA: E450 (*χ*^2^ = 0.376, uncorrected *p*=0.540, corrected *p*\>0.99); CSC1 (*χ*^2^ = 34.0, uncorrected *p*=5.64×10^−9^, corrected *p*=3.39×10^−8^); Co100 (*χ*^2^ = 5.13, uncorrected *p*=0.024, corrected *p*=0.141). Planned contrast between TOP-GFP^low^ + MFCM vs TOP-GFP^low^ + MFCM + PHA: E450 (*χ*^2^ = 61.0, uncorrected *p*=5.71×10^−15^, corrected *p*=3.43×10^−14^); CSC1 (*χ*^2^ = 43.5, uncorrected *p*=4.14×10^−11^, corrected *p*=2.48×10^−10^); Co100 (*χ*^2^ = 17.6, uncorrected *p*=2.67×10^−5^, corrected *p*=1.60×10^−4^). Planned contrast between TOP-GFP^whole^ vs TOP-GFP^whole^ + PHA: E450 (*χ*^2^ = 68.3, uncorrected *p*=1.43×10^−16^, corrected *p*=8.56×10^−16^); CSC1 (*χ*^2^ = 72.2, uncorrected *p*=1.96×10^−17^, corrected *p*=1.17×10^−16^); Co100 (*χ*^2^ = 20.2, uncorrected *p*=6.91×10^−6^, corrected *p*=4.14×10^−5^). Additional details for this experiment can be found at <https://osf.io/k9vce/>.](elife-45426-fig2){#fig2}

As outlined in the Registered Report ([@bib11]), we planned to conduct six comparisons using the Bonferroni correction to adjust for multiple comparisons, making the *a priori* significance threshold 0.0083. We performed Extreme Limiting Dilution Analysis (ELDA) ([@bib19]) and tested for pairwise differences in frequency between groups (see [Figure 2](#fig2){ref-type="fig"} figure legend). The sample sizes were determined *a priori* to detect the effects based on the originally reported data. We found that the test between TOP-GFP^high^ and TOP-GFP^low^ cells was statistically significant for Co100 and E450 cultures, but not CSC1. Treatment with HGF, or MFCM, resulted in a statistically significant increase in clonogenicity in TOP-GFP^low^ cells from the Co100 culture, but not E450 or CSC1 cultures. The comparison of HGF treatment, with or without PHA665752, in TOP-GFP^low^ cells was statistically significant for the CSC1 culture, but not the Co100 or E450 cultures, while the comparison of MFCM treatment, with or without PHA665752, in TOP-GFP^low^ cells was statistically significant for all three cultures. Furthermore, the differences observed in TOP-GFP^whole^ cells with or without PHA665752 were statistically significant for all three cultures. To summarize, for this experiment we found results that were in the same direction as the original study, except for treatment of TOP-GFP^whole^ cells with PHA665752, and statistical significance that varied among the three cultures tested as well as the original study.

Tumorigenicity of TOP-GFP CSC culture {#s2-3}
-------------------------------------

We also examined the frequency TOP-GFP cells form tumors when injected into nude mice. This experiment is similar to what was reported in Figure 7E of [@bib56] and described in Protocol 4 in the Registered Report ([@bib11]). While the original study included TOP-GFP^low^ cells co-injected with myofibroblasts and TOP-GFP^whole^ cells, this replication attempt was restricted to TOP-GFP^high^, TOP-GFP^low^, and TOP-GFP^low^ cells co-injected with MFCM. The original study also reported results from two clones, while this replication attempt utilized a single clone. As stated in the Registered Report, we identified the clone to use as the one with the largest observed difference in clonogenicity between untreated TOP-GFP^high^ and TOP-GFP^low^ cells, which, as described above, was the E450 culture. Different cell numbers were injected into female nude mice and blindly analyzed for tumor formation after nine weeks. We found the frequency of tumorigenicity was similar when TOP-GFP^high^ cells (1 in every 3332, 95% CI \[9174, 1210\]) or TOP-GFP^low^ cells (1 in every 2744, 95% CI \[7377, 1020\]) were injected ([Table 1](#table1){ref-type="table"}), which was not a statistically significant difference (*χ*^2^ = 0.084, uncorrected *p*=0.772, corrected *p*\>0.99). The addition of MFCM to TOP-GFP^low^ cells resulted in an increased frequency of tumorigenicity (1 in every 774, 95% CI \[2268, 264\]), which was not statistically significant when compared to untreated TOP-GFP^low^ cells (*χ*^2^ = 3.32, uncorrected *p*=0.069, corrected *p*=0.137). The original study reported for each of the two clones tested (C100.B5 and C100.G7) the TOP-GFP^high^ fraction was more effective in inducing tumors (C100.B5:\~1 in every 37, 95% CI \[92, 15\]; C100.G7:\~1 in every 961, 95% CI \[2498, 369\]) than the TOP-GFP^low^ fraction (C100.B5:\~1 in every 6939, 95% CI \[18841, 2555\]; C100.G7: frequency estimate unable to be determined) and that tumorigenicity was increased when TOP-GFP^low^ cells were co-injected with MFCM (C100.B5:\~1 in every 310, 95% CI \[789, 122\]; C100.G7:\~1 in every 2352, 95% CI \[5236, 1056\]) ([@bib56]). To summarize, for this experiment we found results that were in the same direction as the original study for the comparison between TOP-GFP^low^ with or without MFCM, but not for the comparison of TOP-GFP^low^ and TOP-GFP^high^, and not statistically significant where predicted.

10.7554/eLife.45426.006

###### Tumorigenicity assay of TOP-GFP culture.

Cell numbers from the indicated populations were injected into female athymic nude mice. Cells were left untreated or treated with 1:2 dilution of MFCM for 2 hr before injection. The number of successful tumor initiations after nine weeks out of four injected mice for each condition is reported. Planned contrast between TOP-GFP^low^ vs TOP-GFP^high^ (*χ*^2^ = 0.084, uncorrected *p*=0.772, corrected *p*\>0.99). Planned contrast between TOP-GFP^low^ vs TOP-GFP^low^ + MFCM (*χ*^2^ = 3.32, uncorrected *p*=0.069, corrected *p*=0.137). Additional details for this experiment can be found at <https://osf.io/j73xu/>.

  Line   Condition            10    100   1000   5000
  ------ -------------------- ----- ----- ------ ------
  E450   TOP-GFP Low          0/4   0/4   2/4    3/4
         TOP-GFP High         0/4   0/4   3/4    2/4
         TOP-GFP Low + MFCM   0/4   2/4   2/4    4/4

Meta-analysis of original and replication effects {#s2-4}
-------------------------------------------------

We performed a meta-analysis using a random-effects model, where possible, to combine each of the effects described above as pre-specified in the confirmatory analysis plan ([@bib11]). To provide a standardized measure of the effect, a common effect size was calculated for each effect from the original and replication studies. Cohen's *ω* is a standardized measure of the association between two variables, in this case the cells tested and clonogenic, or tumorigenic, frequency. The estimate of the effect size of one study, as well as the associated uncertainty (i.e. confidence interval), compared to the effect size of the other study provides another approach to compare the original and replication results ([@bib9]; [@bib54]). Importantly, the width of the confidence interval for each study is a reflection of not only the confidence level (e.g. 95%), but also variability of the sample (e.g. *SD*) and sample size.

There were six comparisons of the *in vitro* clonogenicity assay, which were reported in [Figure 2](#fig2){ref-type="fig"} of this study and Figure 6D of [@bib56]. The effect size point estimates of the original study for each of the effects was not within the 95% CI of the replication results, and vice versa ([Figure 3A](#fig3){ref-type="fig"}). Furthermore, the effect sizes were larger in the original study, compared to the three TOP-GFP cultures tested in this replication attempt, with the exception of treatment of TOP-GFP^whole^ cells with or without PHA665752. The meta-analyses were statistically significant for the comparison of untreated TOP-GFP^low^ and MFCM-treated TOP-GFP^low^ (*p*=0.047), but not for the other five comparisons (see [Figure 3](#fig3){ref-type="fig"} figure legend). Additionally, for the comparison of untreated TOP-GFP^low^ and untreated TOP-GFP^high^ as well as untreated TOP-GFP^low^ and HGF treated TOP-GFP^high^, the large CI of the meta-analyses along with statistically significant Cochran's *Q* tests (*p*=0.0085 and *p*=0.0028, respectively) suggest heterogeneity between the original and replication studies.

![Meta-analyses of each effect.\
Effect size and 95% confidence interval are presented for [@bib56], the results from this replication study (RP:CB), and a random effects meta-analysis of the effects. Cohen's *ω* is a standardized measure of the association between the cells tested and clonogenic, or tumorigenic, frequency. The higher the value, the stronger the association, with an effect size of zero indicating there was no association. Sample sizes used in [@bib56] and RP:CB are reported under the study name. (**A**) Comparison of clonogenic frequency between the indicated treated, or untreated, populations of TOP-GFP CSC cultures. TOP-GFP^low^ vs TOP-GFP^high^ (meta-analysis *p*=0.094); TOP-GFP^low^ vs TOP-GFP^low^ + HGF (meta-analysis *p*=0.110); TOP-GFP^low^ vs TOP-GFP^low^ + MFCM (meta-analysis *p*=0.047); TOP-GFP^low^ + HGF vs TOP-GFP^low^ + HGF + PHA (meta-analysis *p*=0.218); TOP-GFP^low^ + MFCM vs TOP-GFP^low^ + MFCM + PHA (meta-analysis *p*=0.085); TOP-GFP^whole^ vs TOP-GFP^whole^ + PHA (meta-analysis *p*=0.498). (**B**) Comparison of frequency of tumorigenicity between the indicated treated, or untreated, populations of TOP-GFP CSC cultures injected into mice. TOP-GFP^low^ vs TOP-GFP^high^ (meta-analysis *p*=0.330); TOP-GFP^low^ vs TOP-GFP^low^ + MFCM (meta-analysis *p*=0.033). Additional details for these meta-analyses can be found at <https://osf.io/g4ewk/>.](elife-45426-fig3){#fig3}

There were two comparisons of the *in vivo* tumorigenicity assay, which were reported in [Table 1](#table1){ref-type="table"} of this study and Figure 7E of [@bib56]. Similar to the clonogenicity assay, the effect sizes were larger in the original study compared to this replication attempt, and the point estimates of each study were not within the 95% CI of the other study ([Figure 3B](#fig3){ref-type="fig"}). The meta-analysis of the TOP-GFP^low^ and TOP-GFP^high^ comparison was not statistically significant (*p*=0.330) with a large 95% CI and a statistically significant Cochran's *Q* test (*p*=1.35×10^−55^) that suggests heterogeneity between the original and replication studies. The meta-analysis of untreated TOP-GFP^low^ and MFCM treated TOP-GFP^low^ was statistically significant (*p*=0.033), suggesting the null hypothesis that MFCM treatment does not impact tumorigenicity of TOP-GFP^low^ cells can be rejected; however, the large 95% CI and a statistically significant Cochran's *Q* test (*p*=0.011) suggest heterogeneity between the original and replication studies.

This direct replication provides an opportunity to understand the present evidence of these effects. Any known differences, including reagents and protocol differences, were identified prior to conducting the experimental work and described in the Registered Report ([@bib11]). However, this is limited to what was obtainable from the original paper and through communication with the original authors, which means there might be particular features of the original experimental protocol that could be critical, but unidentified. So while some aspects, such as the TOP-GFP reporter plasmid, cell surface markers, treatment conditions of cultures, Co100 culture, and mouse strain were maintained, others were unknown or not easily controlled for. These include variables such as cell line genetic drift ([@bib20]; [@bib27]), genetic heterogeneity of mouse inbred strains ([@bib4]), the microbiome of recipient mice ([@bib34]), housing temperature in mouse facilities ([@bib29]), lot variability of key reagents such as HGF and PHA-665752 ([@bib31]), and similarities and differences in patient characteristics ([@bib28]). Environmental differences such as husbandry staff, bedding type and source, light levels, and other intangibles, all of which, by necessity, differed between the studies also affect experimental outcomes with mice ([@bib18]; [@bib22]; [@bib39]; [@bib51]). The difference in HGF production in conditioned medium between the original study and this replication attempt, as described above, is another factor to consider. Also, differences in CSC features between the cultures used in this replication attempt, as well as the original study, is another important factor to consider. This includes the expression of the cell surface markers between the TOP-GFP^low^ and TOP-GFP^high^ populations, particularly CD24 and CD44, which have been reported as Wnt target genes ([@bib50]; [@bib58]). This could be due to differences in lentiviral integration and copy number of the TOP-GFP reporter, clonal artifacts, and genetic differences between the cancer cells the cultures were derived from as well as genetic drift during passaging of the cultures ([@bib2]). Whether these or other factors influence the outcomes of this study is open to hypothesizing and further investigation, which is facilitated by direct replications and transparent reporting.

Materials and methods {#s3}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                                      Designation                                     Source or reference                                                                               Identifiers                                                                                     Additional\
  (species) or resource                                                                                                                                                                                                                                                                                                information
  ------------------------------------------------------------------ ----------------------------------------------- ------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- -----------------------------------------------
  Cell line (*Homo sapiens*)                                         Co100                                           doi:[10.1038/](https://dx.doi.org/10.1038/ncb2048)[ncb2048](https://dx.doi.org/10.1038/ncb2048)                                                                                                   shared by\
                                                                                                                                                                                                                                                                                                                       Medema lab, University of\
                                                                                                                                                                                                                                                                                                                       Amsterdam

  Cell line (*H. sapiens*, female)                                   CSC1                                            ProMab Biotechnologies                                                                            cat\# CC100103                                                                                  

  Cell line (*H. sapiens*, female)                                   E450                                            this paper                                                                                                                                                                                        

  Cell line (*H. sapiens*, female)                                   18Co                                            ATCC                                                                                              cat\# CRL-1459; RRID:[CVCL_2379](https://scicrunch.org/resolver/CVCL_2379)                      

  Strain, strain background (*Mus musculus*, Athymic Nude, female)   athymic nude                                    Charles River                                                                                     Strain code: 490; RRID:[IMSR_CRL:490](https://scicrunch.org/resolver/IMSR_CRL:490)              

  Recombinant DNA reagent                                            TOP-GFP                                         doi:[10.1038/nature01593](https://dx.doi.org/10.1038/nature01593)                                 RRID:[Addgene_14715](https://scicrunch.org/resolver/Addgene_14715)                              shared by Medema lab, University of Amsterdam

  Chemical compound, drug                                            HGF                                             Sigma-Aldrich                                                                                     cat\# H5791                                                                                     lot\# MKBT3102V

  Chemical compound, drug                                            PHA-665752                                      Sigma-Aldrich                                                                                     cat\# PZ0147                                                                                    

  Other                                                              Matrigel                                        Corning                                                                                           cat\# 356230                                                                                    

  Antibody                                                           PE-conjugated anti-CD133                        Miltenyi Biotec                                                                                   cat\# 130-098-826; clone: AC133; RRID:[AB_2660882](https://scicrunch.org/resolver/AB_2660882)   1:100 dilution

  Antibody                                                           PE-conjugated anti-CD24                         BD Biosciences                                                                                    cat\# 560991; clone ML5; RRID:[AB_10563074](https://scicrunch.org/resolver/AB_10563074)         1:100 dilution

  Antibody                                                           APC-conjugated anti-CD29                        BD Biosciences                                                                                    cat\# 561794; clone: MAR4; RRID:[AB_10898163](https://scicrunch.org/resolver/AB_10898163)       1:100 dilution

  Antibody                                                           PE-conjugated anti-CD166                        R and D Systems                                                                                   cat\# FAB6561P; clone: 105902; RRID:[AB_2223887](https://scicrunch.org/resolver/AB_2223887)     1:100 dilution

  Antibody                                                           APC-conjugated anti-CD44                        BD Biosciences                                                                                    cat\# 560890; clone: G44-26; RRID:[AB_2033959](https://scicrunch.org/resolver/AB_2033959)       1:100 dilution

  Antibody                                                           PE-conjugated mouse IgG1 isotype control        Miltenyi Biotec                                                                                   cat\# 130-098-106; clone: X-56; RRID:[AB_2661463](https://scicrunch.org/resolver/AB_2661463)    1:100 dilution

  Antibody                                                           APC-conjugated mouse IgG2b, κ isotype control   BD Biosciences                                                                                    cat\# 555745; clone: 27--35; RRID:[AB_398612](https://scicrunch.org/resolver/AB_398612)         1:100 dilution

  Antibody                                                           PE-conjugated mouse IgG2a, κ isotype control    BD Biosciences                                                                                    cat\# 555574; clone: G155-178; RRID:[AB_395953](https://scicrunch.org/resolver/AB_395953)       1:100 dilution

  Antibody                                                           APC-conjugated mouse IgG1 isotype control       BD Biosciences                                                                                    cat\# 555751; clone: MOPC-21; RRID:[AB_398613](https://scicrunch.org/resolver/AB_398613)        1:100 dilution

  Software, algorithm                                                FACS Sortware sorter                            BD Biosciences                                                                                    RRID:[SCR_016722](https://scicrunch.org/resolver/SCR_016722)                                    version 1.2.0.142

  Software, algorithm                                                HCS Studio Cell Analysis                        Thermo Fisher Scientific                                                                          RRID:[SCR_016787](https://scicrunch.org/resolver/SCR_016787)                                    version 6.6.0

  Software, algorithm                                                FACSDiva                                        BD Biosciences                                                                                    RRID:[SCR_016722](https://scicrunch.org/resolver/SCR_016722)                                    version 6.1.3 or 8.0.1

  Software, algorithm                                                FlowJo                                          Tree Star, Inc                                                                                    RRID:[SCR_008520](https://scicrunch.org/resolver/SCR_008520)                                    version 10

  Software, algorithm                                                R Project for statistical computing             <https://www.r-project.org>                                                                       RRID:[SCR_001905](https://scicrunch.org/resolver/SCR_001905)                                    version 3.5.1
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

As described in the Registered Report ([@bib11]), we attempted a replication of the experiments reported in Figures 2F, 6D, and 7E of [@bib56]. A detailed description of all protocols can be found in the Registered Report ([@bib11]) and are described below with additional information not listed in the Registered Report, but needed during experimentation.

Cell culture {#s3-1}
------------

Three cultures of CSCs were isolated/obtained for this study. Co100 cells, which were used in the original study, were shared by Dr. Jan Paul Medema (University of Amsterdam). CSC1 cells were obtained commercially from primary human colorectal tumor tissue from a female Caucasian patient at the age of 65 (ProMab Biotechnologies, cat\# CC100103; datasheet available at <https://osf.io/det4j/>). E450 cells were isolated as described in the Registered Report ([@bib11]) from a freshly excised human colon adenocarcinoma tumor fragment from a female Caucasian patient at the age of 78. Of note, E450 was the only viable spheroidal culture that was successfully derived from twelve different colon tissue fragments that were attempted. This is slightly lower (8.3%) then the range of what was shared by the original authors during preparation of the Registered Report (10--20%: [@bib11]) and previously reported efficiency rates (15%: [@bib42]; 11%: [@bib3]; 33%: [@bib35]), although methods to increase efficiency have since been reported (73%; [@bib36]). Patient phenotype (e.g. age, sex, ethnicity, diagnosis) for E450 are available at <https://osf.io/ysf58/>. Approval was obtained from Western Institutional Review Board (WIRB) (protocol MR \#0701) and were in full compliance with good clinical practices as defined under the U.S. Food and Drug Administration (FDA) regulations, U.S. Department of Health and Human Services (HHS) regulations, and the International Conference on Harmonisation (ICH) guidelines. Shared samples and data were de-identified for this study. CSCs were maintained at 37°C in a humidified atmosphere at 5% CO~2~ in CSC medium (modified neurobasal A medium supplemented with 1X N2 supplement, lipid mixture-1 (1 ml/500 ml medium), 20 ng/ml fibroblast growth factor-basic, and 50 ng/ml epidermal growth factor) and passaged as described in the Registered Report ([@bib11]) with additional details available at <https://osf.io/dtbvp/>. 18Co cells (ATCC, cat\# CRL-1459, RRID:[CVCL_2379](https://scicrunch.org/resolver/CVCL_2379)) were maintained at 37°C in a humidified atmosphere at 5% CO~2~ in Eagle's Minimum Essential Medium supplemented with 10% FBS, 500 U/ml penicillin, 500 U/ml streptomycin, and 1.25 µg/ml amphotericin B. Quality control data confirming the cells were free of mycoplasma contamination (MycoAlert Mycoplasma Detection kit; Lonza, cat\# LT07-318) is available at <https://osf.io/xzh9t/>.

Lentiviral infection {#s3-2}
--------------------

TCF/LEF-1 responsive promoter to drive expression of green fluorescent protein (GFP) (TOP-GFP, RRID:[Addgene_14715](https://scicrunch.org/resolver/Addgene_14715)) was shared Dr. Jan Paul Medema (University of Amsterdam) with permission from Dr. Laurie Ailles (University Health Network; University of Toronto). Spheroidal cultures were transduced with lentiviral particles to express TOP-GFP which were produced by Cyagen Biosciences, Inc (Santa Clara, California) with a titer of 3.66 × 10^8^ TU/ml as determined by quantitative PCR using a fragment in the WPRE region of the lentiviral vector amplified from genomic DNA of transduced HEK293 cells. Dissociated spheroidal cultures were each transduced for 24 hr with 20 µl concentrated lentivirus per 1 × 10^6^ cells in 10 ml CSC medium supplemented with 8 µg/l polybrene before medium was replaced. Cells were cultured for 4 weeks before isolation of single-cell-derived cultures by fluorescence-activated cell sorting (FACS). FACS was performed on an Influx cell sorter (BD Biosciences) and analyzed with FACS Sortware sorter software (BD Biosciences, RRID:[SCR_016722](https://scicrunch.org/resolver/SCR_016722)), version 1.2.0.142. Spheroids were dissociated as described in the Registered Report ([@bib11]) and propidium iodide (PI) was added at 250 ng/ml immediately prior to sorting. Single, PI-negative, GFP-positive cells were sorted and deposited into individual wells of ultralow-adhesion 96-well plates containing 200 µl/well CSC medium. Four 96-well plates were tested for each culture with one viable single-cell clone generated from the CSC1 culture (0.26% efficiency), three clones from the E450 culture (0.78% efficiency, and eight clones from the Co100 culture (2.08% efficiency), which were near the range of what was shared by the original authors during preparation of the Registered Report (\~1%: [@bib11]). One clone was randomly selected from each culture for further analysis. Over a period of 13 weeks, spheroid cultures arising from single cells were gradually expanded into larger ultralow-adhesion flasks. Microscopy images of cultures were acquired with a CellInsight CX7 High-Content Screening (HCS) Platform (ThermoFisher Scientific) and HCS Studio Cell Analysis software (ThermoFisher Scientific, RRID:[SCR_016787](https://scicrunch.org/resolver/SCR_016787)) version 6.6.0, build 8153.

Flow cytometry analysis of cell surface markers {#s3-3}
-----------------------------------------------

Spheroid cultures were dissociated with trypsin and resuspended at a final concentration of 1 × 10^6^ cells/ml in FACS buffer (PBS supplemented with 2% fetal bovine serum (FBS), 1X antifungal/antibiotic, and 2 mM EDTA). Cells were stained at 1:100 dilution with PE-conjugated monoclonal anti-CD133 (Miltenyi Biotec, cat\# 130-098-826, clone AC133, RRID:[AB_2660882](https://scicrunch.org/resolver/AB_2660882)), PE-conjugated monoclonal anti-CD24 (BD Biosciences, cat\# 560991, clone ML5, RRID:[AB_10563074](https://scicrunch.org/resolver/AB_10563074)) and APC-conjugated monoclonal anti-CD29 (BD Biosciences, cat\# 561794, clone MAR4, RRID:[AB_10898163](https://scicrunch.org/resolver/AB_10898163)), or PE-conjugated monoclonal anti-CD166 (R and D Systems, cat\# FAB6561P, clone 105902, RRID:[AB_2223887](https://scicrunch.org/resolver/AB_2223887)) and APC-conjugated monoclonal anti-CD44 (BD Biosciences, cat\# 560890, clone G44-26, RRID:[AB_2033959](https://scicrunch.org/resolver/AB_2033959)) and incubated at 4°C in the dark for 10 min. Cells were also stained with 1:100 dilution of control antibodies: PE-conjugated monoclonal mouse IgG1 isotype control (Miltenyi Biotec, cat\# 130-098-106, clone X-56, RRID:[AB_2661463](https://scicrunch.org/resolver/AB_2661463)), APC-conjugated monoclonal mouse IgG2b, κ isotype control (BD Biosciences, cat\# 555745, clone 27--35, RRID:[AB_398612](https://scicrunch.org/resolver/AB_398612)), PE conjugated monoclonal mouse IgG2a, κ isotype control (BD Biosciences, cat\# 555574, clone G155-178, RRID:[AB_395953](https://scicrunch.org/resolver/AB_395953)), or APC-conjugated monoclonal mouse IgG1 isotype control (BD Biosciences, cat\# 555751, clone MOPC-21, RRID:[AB_398613](https://scicrunch.org/resolver/AB_398613)). Cells were washed by adding 20 times the reaction volume of FACS buffer and gently inverting tubes three times. Cells were centrifuged at 1000 RPM for 10 min, supernatant was carefully aspirated, and the cells were resuspended in 100 µl FACS buffer. Flow cytometry analysis was performed on a FACSAria II (BD Biosciences) and analyzed with FACSDiva software (BD Biosciences, RRID:[SCR_016722](https://scicrunch.org/resolver/SCR_016722)), version 6.1.3. PI (250 ng/ml) was added to cells just before analysis. FACS data was imported into FlowJo software (Tree Star, Inc, RRID:[SCR_008520](https://scicrunch.org/resolver/SCR_008520)), version 10, after which the scaled compensated values were exported as csv files. These values were then imported into Python 2.7 to perform rectangular gating. Cells were first gated using the forward scatter and propidium-iodide channels (i.e. cells negative for propidium-iodide were retained). Cells were subsequently gated for positive TOP-GFP expression. After this, cells below the 10th percentile and above the 90th percentile of TOP-GFP expression were compared. Gating strategy was described in the Registered Report with additional details available at <https://osf.io/8c43g/> and a representative example depicted in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.

Conditioned medium {#s3-4}
------------------

7.5 × 10^5^ 18 Co cells were seeded in a 75 cm^2^ flask and incubated overnight. The next day, cells were washed twice with PBS and incubated for 24 hr with 10 ml of CSC medium without EGF and FGF-basic. The next day the conditioned medium was collected and cleared by centrifugation for 5 min at 1400 RPM and used at 1:2 dilution in CSC medium for the assays described below. The level of HGF present in MFCM was determined by ELISA (Sigma-Aldrich, cat\# RAB0212) according to manufacturer's instructions with a standard curve. Data are available at <https://osf.io/fpj4u/>.

Limiting-dilution assay {#s3-5}
-----------------------

An initial pilot experiment was performed to assess the potential for the three populations (TOP-GFP^low^ (10% lowest), TOP-GFP^high^ (10% highest), and TOP-GFP^whole^ (total)), without treatment, on the three TOP-GFP CSC cultures (Co100, CSC1, E450). Cells from the different populations were deposited at 1, 2, 4, 6, 8, 12, 16, 20, and 24 cells per well in the number of wells indicated in the Registered Report with additional details available at <https://osf.io/ydfrg/>. Cells were deposited with an Influx cell sorter and analyzed with FACS Sortware sorter software, version 1.2.0.142. Cells were incubated at 37°C in a humidified atmosphere at 5% CO~2~, with culture medium replaced every 4 days. After 14 days of culture, the number of cultures with spheres, and the number of cells per sphere were quantified using automated high-content fluorescence imaging for GFP-positive and Hoechst-positive cells using a CellInsight CX7 High-Content Screening (HCS) Platform and HCS Studio Cell Analysis software. Spheres composed of two or more cells were used to determine clonal frequency which was evaluated by ELDA from the *statmod* R package ([@bib19]), version 1.4.30. Raw data are available at <https://osf.io/ctqu2/> with data aggregated in csv format (<https://osf.io/ydejb/>). Pilot results reported in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}. Based on these results, it was decided that the cell titration would remain the same for the confirmatory experiment, and that the E450 culture would be used for the *in vivo* tumorigenicity assay. Cells from the indicated TOP-GFP population were deposited into 96-well ultralow-adhesion plates with 100 µl of either CSC medium (untreated), CSC medium with 25 ng/ml HGF (Sigma-Aldrich, cat\# H5791, lot\# MKBT3102V), CSC medium with MFCM (1:2 dilution in CSC medium), CSC medium with 25 ng/ml HGF and 500 nM PHA-665752 (Sigma-Aldrich, cat\# PZ0147), CSC medium with MFCM and 500 nM PHA-665752, or CSC medium with 500 nM PHA-665752. Cells were deposited with a FACSAria III (BD Biosciences) and analyzed with FACSDiva software, version 8.0.1. Cells were incubated at 37°C in a humidified atmosphere at 5% CO~2~, with the appropriate culture medium replaced every 4 days. After 14 days of culture, the number of cultures with spheres, and the number of cells per sphere were blindly quantified using automated high-content fluorescence imaging for GFP-positive and Hoechst-positive cells as described for the pilot assay. Raw data are available at <https://osf.io/qwgx4/> with data aggregated in csv format (<https://osf.io/26zp5/>). Clonal frequency and statistical significance was determined by ELDA ([@bib19]).

*In vivo* tumorigenicity assay {#s3-6}
------------------------------

All animal procedures were approved by the Explora BioLabs, Inc animal use committee (IACUC\# SP17-009-005A) and were in accordance with Explora BioLabs, Inc policies on the care, welfare, and treatment of laboratory animals.

Nine-week old female Athymic Nude mice (Charles River, Strain code: 490, RRID:[IMSR_CRL:490](https://scicrunch.org/resolver/IMSR_CRL:490)) were housed in sterile conditions under standard temperature, humidity, and timed lighting conditions with 12 hr light/dark cycles and acclimated to the housing environment for 3 days prior to the initiation of the study. They were housed on bedding material (Corn Cobb, cat\# M-BTM-C8) that was changed bi-weekly. Animals were provided standard diet (Envigo, cat\# 2920X (Irradiated Global 18% Soy Protein Extruded Rodent Diet)) and acidified water (pH 2.5--3.0) throughout the study period *ad libitum*. Body weights were measured on Day −1 for randomization and the 48 animals were stratified into 12 groups to obtain similar average body weight among groups. Following cell-injection, animal health, body weight, and tumor observation were recorded weekly and are available at <https://osf.io/xs9up/>. Tumor volumes were calculated from caliper measurements using the formula (volume = 1/2(length\*width^2^). Experimental work was performed blinded to the identity of the sample the mice were injected with.

Mice were injected, on Day 0, with TOP-GFP transduced cultures (E450 culture) at 10, 100, 1000, or 5000 cells from the 10% lowest or 10% highest TOP-GFP intensities that were deposited, by FACS (FACSAria II with FACSDiva software, version 6.1.3), in a 96-well ultralow-adhesion plate and resuspended in 100 µl of CSC medium or MFCM (generated as described above and in the Registered Report \[[@bib11]\]) and incubated at 37°C for 2 hr. After this incubation, plates were shipped to the facility that performed the mouse injection/monitoring (\~30 min) where the cells and medium (100 µl) were mixed with growth factor reduced Matrigel (Corning, cat\# 356230) at a 1:1 ratio and injected subcutaneously into the right flank of the female mice using a sterile 25 G needle and 1 ml syringe as described in the Registered Report ([@bib11]). Mice were monitored for tumor formation for nine weeks after injection, the indicated study endpoint in the Registered Report. To explore if the frequency changed, the mice were monitored an additional 2 weeks; however we did not observe any new tumor initiations. Tumor-initiating cell frequency was determined by ELDA ([@bib19]).

Statistical analysis {#s3-7}
--------------------

Statistical analysis was performed with R software (RRID:[SCR_001905](https://scicrunch.org/resolver/SCR_001905)), version 3.5.1 ([@bib43]). All data, csv files, and analysis scripts are available on the OSF (<https://osf.io/pgjhx/>). Confirmatory statistical analysis was pre-registered (<https://osf.io/rscpj/>) before the experimental work began as outlined in the Registered Report ([@bib11]). Data were checked to ensure assumptions of statistical tests were met. The fitted models to determine the stem cell frequency for different groups were compared using likelihood ratio tests using the asymptotic chi-square approximation to the log-ratio ([@bib19]). When described in the results, the Bonferroni correction, to account for multiple testings, was applied to the alpha error or the *p*-value. The Bonferroni corrected value was determined by divided the uncorrected value (0.05) by the number of tests performed. The confidence intervals for the Cohen's *ω* estimates were determined using a Fisher's z' transformation ([@bib46]). A meta-analysis of a common original and replication effect size was performed with a random effects model and the *metafor* R package ([@bib57]), version 2.0--0 (<https://osf.io/g4ewk/>). The original study data of the stem cell frequency and 95% CI pertaining to Figure 6D was extracted *a priori* from the published figure and used to create simulated data sets with preserved sampling structure using ELDA ([@bib19]) during preparation of the experimental design, while the original study data pertaining to Figure 7E was published in the original paper ([@bib56]). The C100.B5 line from the original study was used in the meta-analysis for the tumorigenicity assay, but not the C100.G7 line because an estimate for TOP-GFP^low^ could not be calculated (i.e. estimate was infinity because of no observable responses). The summary data was published in the Registered Report ([@bib11]) and used in the power calculations to determine the sample sizes for this study.

Data availability {#s3-8}
-----------------

Additional detailed experimental notes, data, and analysis are available on OSF (RRID:[SCR_003238](https://scicrunch.org/resolver/SCR_003238)) (<https://osf.io/pgjhx/>; [@bib10]). This includes the R Markdown file (<https://osf.io/d6qp8/>) that was used to compose this manuscript, which is a reproducible document linking the results in the article directly to the data and code that produced them ([@bib16]). Flow cytometry data for this study has also been deposited at Flow Repository (RRID:[SCR_013779](https://scicrunch.org/resolver/SCR_013779); [@bib52]), where it is directly accessible at <https://flowrepository.org/id/FR-FCM-ZYUG>.

Deviations from registered report {#s3-9}
---------------------------------

We planned to isolate two CSC spheroidal cultures from patient samples, but due to only obtaining a single viable spheroidal culture from the 12 different colon tissue fragments that were attempted, we obtained another culture commercially that was also derived from primary human colorectal tumor tissue. The Registered Report indicated we would perform the flow cytometry analysis and clonogenicity assay on three different single-cell TOP-GFP clones from each of the three cultures, while the results reported in this study are from one random single-cell TOP-GFP clone from each culture. This was due to the CSC1 culture only producing one viable clone as stated in the 'Lentiviral infection' section above. We also did not perform the statistical analysis listed in Protocol 2 for the cell surface markers since the observed variation was from the same population of cells. Additional materials and instrumentation not listed in the Registered Report, but needed during experimentation are also listed.

The Reproducibility Project: Cancer Biology would like to thank Dr Jan Paul Medema (University of Amsterdam) and Dr Giorgio Stassi (University of Palermo) for sharing critical information, data, and reagents, specifically the Co100 cells and TOP-GFP plasmid used in the original study. We want to thank Dr Laurie Ailles (University Health Network; University of Toronto) for providing permission for the TOP-GFP plasmid. We want to thank I Janette Delgadillo (Explora BioLabs, Inc) for providing study oversight for the animal experiments and Dr Lawrence R Blocher (Minerva Resource, Inc) for human colon adenocarcinoma tumor fragment collection. We would also like to thank the following companies for generously donating reagents to the Reproducibility Project: Cancer Biology; American Type and Tissue Collection (ATCC), Applied Biological Materials, BioLegend, Charles River Laboratories, Corning Incorporated, DDC Medical, EMD Millipore, Harlan Laboratories, LI-COR Biosciences, Mirus Bio, Novus Biologicals, Sigma-Aldrich, and System Biosciences (SBI).

Additional information {#s4}
======================
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Human subjects: Approval was obtained from Western Institutional Review Board (WIRB) (protocol MR \#0701) and were in full compliance with good clinical practices as defined under the US Food and Drug Administration (FDA) regulations, US Department of Health and Human Services (HHS) regulations, and the International Conference on Harmonisation (ICH) guidelines.

Animal experimentation: All animal procedures were approved by the Explora BioLabs, Inc animal use committee (IACUC\# SP17-009-005A) and were in accordance with Explora BioLabs, Inc policies on the care, welfare, and treatment of laboratory animals.
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###### The ARRIVE guidelines checklist.

Data availability {#s6}
=================

Additional detailed experimental notes, data, and analysis are available on OSF (RRID:SCR_003238) (<https://osf.io/pgjhx/>; Essex et al., 2019). This includes the R Markdown file (<https://osf.io/d6qp8/>) that was used to compose this manuscript, which is a reproducible document linking the results in the article directly to the data and code that produced them (Hartgerink, 2017). Flow cytometry data for this study has also been deposited at Flow Repository (RRID:SCR_013779; Spidlen et al., 2012), where it is directly accessible at <https://flowrepository.org/id/FR-FCM-ZYUG>.

The following datasets were generated:

EssexAPinedaJAcharyaGXinHEvansJIornsETsuiRDenisAPerfitoNErringtonTM2019Study 9: Replication of Vermeulen et al., 2010 (Nature Cell Biology)Open Science Framework10.17605/OSF.IO/PGJHX

EssexAPinedaJAcharyaGXinHEvansJIornsETsuiRDenisAPerfitoNErringtonTM2019Replication Study: Wnt activity defines colon cancer stem cells and is regulated by the microenvironmentFlowRepositoryFR-FCM-ZYUG
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Decision letter

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Replication Study: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment\" for consideration at *eLife*. Your article has been evaluated by Sean Morrison as the Senior Editor, a Reviewing Editor, and three reviewers.

There are a few issues identified by the reviewers that need to be addressed before acceptance, as outlined below:

1\) Address the concerns raised by reviewer 1 regarding the limiting dilution data as well as provide the primary data for these experiments. In addition, specify the type of Matrigel used in the in vivo experiments given the divergence in results between the two studies.

2\) As indicated by reviewer 2, comment on any possible discrepancy between HGF production in conditioned medium from the original study to this replication study that may account for variation in results. Also, comment on subsequent work that has linked WNT signatures to clonogenicity/stemness and if any have validated these particular markers in CRC cells.

*Reviewer \#1:*

The current Replication Study indicates that the original observations can be reproduced to a large extent. Several key features show clear differences from the original study. These include clonogenic efficacy, expression of specific markers and in vivo tumorigenicity. Below a point by point assessment of this differences is given as well as several other details.

1\) In the Registered Report it was noted that multiple subclones would be tested. It is unclear why the authors decided to divert from this original plan and only test one clone. This should be explained, but maybe more important, be revised.

2\) The in vivo tumorigenicity is the main feature that is different from the Original study. In the report it is not noted what Matrigel was used to inject the tumor cells. If this is not growth factor reduced the data can be explained quite easily. This information should be given.

3\) CD24 and in particular CD44, are well-established Wnt target genes and reporters (e.g. Wielenga et al., 1999). The current authors report that Wnt-low cells display lower CD44 and CD24 levels in some lines. This warrants further discussion.

4\) Widespread variation in clonogenic potential with specific cell populations has been reported beyond Wnt activity levels. For example Cd133+ cells are (Ricci-Vitiani et al., 2007, and O\'Brien et al., 2007) or are not (Shmelkov et al., 2008) associated with the tumorigenic population. In addition, even in similar lines different results are obtained; for example compare Dittfeld et al., 2009 with Chen et al., 2011 regarding the use of Cd133 in HCT116 cells to define a clonogenic subfraction. The current results should be described in this context.

5\) The establishment of lines from primary tissue is with 1 in 12 extremely inefficient in comparison with our experience (\~50%) and published literature (50-90%). This should be described better as it may impact on the data as well.

*Reviewer \#2:*

I do not have major technical concerns for this replication study that would require additional experimental work.

*Reviewer \#3:*

Essex, Evans and colleagues have undertaken a replication analysis of selected studies from the 2010 manuscript by Vermeulen et al. (Vermeulen et al., 2010). The replication study focused on cell surface markers of presumptive Wnt pathway-high cancer stem cells, the clonogenicity in vitro of presumptive Wnt pathway-high cancer stem cells vs. Wnt pathway-low cells and how cancer-associated myofibroblast-associated secreted factors might influence clonogenicity; and the tumorigenic growth potential of Wnt pathway-high cells and how tumor-associated myofibroblast-secreted factors might impact on tumorigenic potential.

The replication study was able to show that only three of the five cell surface markers previously linked to Wnt pathway-high transcriptional activity status in three spheroid cancer cell line models could be confirmed. The authors confirmed that in vitro clonogenicity was highest in cells with Wnt pathway-high status and that clonogenic potential of cells low Wnt pathway activity was increased by myofibroblast-secreted factors, such as HGF. Some of the findings on clonogenicity were of less certain statistical significance. The authors did not find a difference in tumorigenicity between the cells with Wnt pathway-high vs. Wnt pathway-low transcriptional status, though tumorigenicity was increased with myofibroblast-secreted factors, but not in a statistically significant manner.

The replication work is solidly performed and presented and interpreted in a reasonable manner.

No major comments are offered.

10.7554/eLife.45426.017

Author response

> 1\) Address the concerns raised by reviewer 1 regarding the limiting dilution data as well as provide the primary data for these experiments. In addition, specify the type of Matrigel used in the in vivo experiments given the divergence in results between the two studies.

The limiting dilution data were available via a private link, which will later be made public. We have also added the data as figure 2---figure supplement 1. In the revised manuscript we also included in the source of the Matrigel used, which was growth factor reduced as described in the Registered Report.

> 2\) As indicated by reviewer 2, comment on any possible discrepancy between HGF production in conditioned medium from the original study to this replication study that may account for variation in results. Also, comment on subsequent work that has linked WNT signatures to clonogenicity/stemness and if any have validated these particular markers in CRC cells.

We have included further discussion on these two aspects in the revised manuscript.

Reviewer \#1:

> *The current Replication Study indicates that the original observations can be reproduced to a large extent. Several key features show clear differences from the original study. These include clonogenic efficacy, expression of specific markers and* in vivo tumorigenicity. Below a point by point assessment of this differences is given as well as several other details.
>
> 1\) In the Registered Report it was noted that multiple subclones would be tested. It is unclear why the authors decided to divert from this original plan and only test one clone. This should be explained, but maybe more important, be revised.

In the revised article we have further explained this deviation in the 'Lentiviral infection' and 'Deviations from Registered Report' sections of the Materials and methods.

*2) The* in vivo *tumorigenicity is the main feature that is different from the Original study. In the report it is not noted what Matrigel was used to inject the tumor cells. If this is not growth factor reduced the data can be explained quite easily. This information should be given.*

The Matrigel used was growth factor reduced (Corning, cat\# 356230), as described in the Registered Report. We have also included this information in the revised manuscript.

> 3\) CD24 and in particular CD44, are well-established Wnt target genes and reporters (e.g. Wielenga et al., 1999). The current authors report that Wnt-low cells display lower CD44 and CD24 levels in some lines. This warrants further discussion.

We have added further discussion on this observation in the revised manuscript.

> 4\) Widespread variation in clonogenic potential with specific cell populations has been reported beyond Wnt activity levels. For example Cd133+ cells are (Ricci-Vitiani et al., 2007, and O\'Brien et al., 2007) or are not (Shmelkov et al., 2008) associated with the tumorigenic population. In addition, even in similar lines different results are obtained; for example compare Dittfeld et al., 2009 with Chen et al., 2011 regarding the use of Cd133 in HCT116 cells to define a clonogenic subfraction. The current results should be described in this context.

We have added this additional context in the revised manuscript.

> 5\) The establishment of lines from primary tissue is with 1 in 12 extremely inefficient in comparison with our experience (\~50%) and published literature (50-90%). This should be described better as it may impact on the data as well.

We have added additional references on the efficiency of establishing lines from primary tissue in the revised manuscript, which are in the range of 11-33%, as well as additional methods that have been published recently demonstrating much higher efficiency (73%). Additionally, of note, in correspondence with the original authors, we were informed that the success rate was 10-20% to form spheroidal cultures from primary tissue samples, which is close to what we observed.
